Skip to main content
Equibles
IRMD logo

IRMD · Iradimed Corp · Metrics

Track IRMD — free

Use IRMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$82.22 +0.35 (+0.43%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.05B
Shares
12.79M

IRMD metrics

87 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$82.22
Market cap
$1.05B

Price action

20 metrics
Price change (1W)
-5.5%
Price change (30D)
-6.1%
Price change (3M)
-14.9%
Price change (6M)
-17.6%
Price change (YTD)
-15.8%
Price change (1Y)
+14.5%
Trailing year
Price change (5Y)
+137.3%
52-week high
$105.15
52-week low
$68.55
Change from 52-week high
-22.1%
Change from 52-week low
+19.4%
Annualized volatility
31.7%
Annualized volatility (3M)
28.9%
Beta
0.6
RSI (14D)
28.2
Price vs SMA 50
-10.4%
Price vs SMA 200
-13.3%
Avg volume (3M)
126,402
Relative volume
1.0
Average dollar volume
$11.63M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
12.79M

Valuation

12 metrics
P / E (TTM)
45.7
Trailing earnings · reciprocal yield 2.2%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
12.1×
reciprocal yield 8.2%
P / book
10.3
reciprocal yield 9.7%
FCF yield
2.4%
TTM · current market cap
Buyback yield
—
P / FCF
41.7
reciprocal yield 2.4%
P / operating cash flow
38.6
reciprocal yield 2.6%
Earnings yield
2.2%

Historical valuation

8 metrics
P / E historical average (3Y)
40.0×
reciprocal yield 2.5%
P / E historical average (5Y)
45.2×
reciprocal yield 2.2%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
1.6%
Trailing 12 months
Payout ratio
68.7%
Shareholder yield
1.5%
Dividend / share (TTM)
$1.27
Dividend growth YoY
+92.4%
Dividend growth streak
1
Last ex-dividend
2026-08-14

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-31

Profitability

9 metrics
Gross margin
75.9%
Operating margin
31.9%
Trailing 12 months
Net margin
26.7%
Gross profit (TTM)
$65.50M
Operating profit (TTM)
$27.55M
Net income (TTM)
$23.05M
Trailing 12 months
Diluted EPS (TTM)
$1.79
FCF margin
29.1%
Effective tax rate
22.5%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.40

Growth

11 metrics
Revenue growth YoY
+0.3%
Year over year
Net income growth YoY
-9.6%
Revenue (TTM)
$86.34M
Trailing 12 months
EPS growth YoY
-8.9%
Shares change YoY
+0.3%
Year over year · more shares
Revenue CAGR (3Y)
+16.3%
Revenue CAGR (5Y)
+21.5%
EPS CAGR (3Y)
+19.7%
EPS CAGR (5Y)
+73.9%
FCF CAGR (3Y)
+23.1%
FCF CAGR (5Y)
+26.2%

Quality

14 metrics
Return on equity
22.7%
Return on assets
20.1%
Debt / equity
—
Current ratio
9.5
EBITDA (TTM)
$29.18M
Free cash flow (TTM)
$25.12M
Quick ratio
8.1
Interest coverage
—
Net debt / EBITDA
-2.0
Return on invested capital
—
Trailing 12 months
Net cash
$59.08M
Latest balance sheet
Cash & equivalents
$59.08M
Total assets
$114.97M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$27.14M
Capital expenditures (TTM)
$2.02M
R&D (TTM)
$3.09M
SG&A (TTM)
—
Stock compensation (TTM)
$2.85M
R&D / revenue
3.6%
Stock compensation / revenue
3.3%

Ownership (13F)

3 metrics
13F filers
214
13F filer change QoQ
-14
Institutional ownership
61.6%

Short interest

3 metrics
Short interest
5.5%
Latest settlement · 8.4 days to cover
Days to cover
8.4d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$122,622
Insider-sentiment score
50 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1325618 CUSIP 46266A109 13F (30d) 94 filings 94 filers Visit website Investor relations